Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2025)
Ultragenyx Pharmaceutical (RARE) reported Non Operating Income of -$934000.0 for Q4 2025, up 79.88% year-over-year from -$519224.4 in Q4 2024, and up 10.45% on a QoQ basis from -$1.0 million in Q3 2025.
Ultragenyx Pharmaceutical (RARE) has 13 years of Non Operating Income data on file, last reported at -$934000.0 in Q4 2025.
- Quarterly Non Operating Income rose 79.88% year-over-year to -$934000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (up 120.0% YoY) and the FY2025 annual result came in at $1.0 million, up 120.0% from the prior year.
- Non Operating Income rose to -$934000.0 in Q4 2025 per RARE's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.1 million in Q3 2024 and bottomed at -$4.6 million in Q4 2024.
- The 5-year median for Non Operating Income is -$557000.0 (2021), against an average of -$412650.0.
- The widest annual swing landed in 2022, when Non Operating Income slumped 1288.06%; it then surged 666.67% in 2023.
- Tracing RARE's Non Operating Income over 5 years: stood at -$410000.0 in 2021, then jumped by 143.9% to $180000.0 in 2022, then surged by 666.67% to $1.4 million in 2023, then slumped by 436.45% to -$4.6 million in 2024, then jumped by 79.88% to -$934000.0 in 2025.
- Per Business Quant, the three latest RARE Non Operating Income figures stand at -$934000.0 (Q4 2025), -$1.0 million (Q3 2025), and $2.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -934,000.00 |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 837,000.00 |
| Dec 31, 2024 | -4.64 Mn |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.61 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | -699,000.00 |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | 308,000.00 |
| Dec 31, 2022 | 180,000.00 |
| Sep 30, 2022 | -1.11 Mn |
| Jun 30, 2022 | -930,000.00 |
| Mar 31, 2022 | 289,000.00 |
| Dec 31, 2021 | -410,000.00 |
| Sep 30, 2021 | -415,000.00 |
| Jun 30, 2021 | -67,000.00 |
| Mar 31, 2021 | -795,000.00 |
| Dec 31, 2020 | 299,000.00 |
| Sep 30, 2020 | 547,000.00 |
| Jun 30, 2020 | 217,000.00 |
| Mar 31, 2020 | -456,000.00 |
| Dec 31, 2019 | 154,000.00 |
| Sep 30, 2019 | -153,000.00 |
| Jun 30, 2019 | -376,000.00 |
| Mar 31, 2019 | -412,000.00 |
| Dec 31, 2018 | 13,000.00 |
| Sep 30, 2018 | -147,000.00 |
| Jun 30, 2018 | -496,000.00 |
| Mar 31, 2018 | -4.96 Mn |
| Dec 31, 2017 | -1.84 Mn |
| Sep 30, 2017 | 3.37 Mn |
| Jun 30, 2017 | 4.41 Mn |
| Mar 31, 2017 | 582,000.00 |
| Dec 31, 2016 | -1.62 Mn |
| Sep 30, 2016 | -46,000.00 |
| Jun 30, 2016 | 159,000.00 |
| Mar 31, 2016 | 865,000.00 |
| Dec 31, 2015 | -1.38 Mn |
| Sep 30, 2015 | 704,000.00 |
| Jun 30, 2015 | 355,000.00 |
| Mar 31, 2015 | -150,000.00 |
| Dec 31, 2014 | 10,000.00 |
| Sep 30, 2014 | -185,000.00 |
| Jun 30, 2014 | 76,000.00 |
| Mar 31, 2014 | -3.29 Mn |
| Dec 31, 2013 | -2.01 Mn |
| Sep 30, 2013 | -667,000.00 |
| Jun 30, 2013 | -343,000.00 |
| Mar 31, 2013 | 12,000.00 |